// App-Quantinova.ai

: INDIVIDUALIZING DURATION OF DUAL ANTIPLATELET THERAPY BASED ON BLEEDING RISK, ISCHEMIC RISK, OR BOTH: AN ANALYSIS FROM THE DUAL ANTIPLATELET THERAPY (DAPT) STUDY

Researchers

Presenter

  • Nino Mihatov

Principal Investigators

  • Eric Secemsky

  • Dean Kereiakes

  • Philippe Gabriel Steg

  • Donald Cutlip

  • Ajay Kirtane

  • Roxana Mehran

  • Bokai Zhao

  • Yang Song

  • C. Michael Gibson

  • Robert Yeh

Medical Centers

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Columbia University Medical Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Myocardial infarction

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved